Anthem Biosciences IPO 2025: Date, GMP, Price, Allotment, Review & Listing
The Anthem Biosciences IPO is set to hit the Indian stock market, generating significant buzz among investors. As a leading Contract Research, Development, and Manufacturing Organization (CRDMO), Anthem Biosciences is well-positioned in the pharmaceutical and biotech sectors. This article provides a comprehensive overview of the Anthem Biosciences IPO, including its dates, price band, Grey Market Premium (GMP), allotment details, financial performance, and expert insights to help you make an informed investment decision.
Join Telegram
Join WhatsApp
Anthem Biosciences IPO Dates & Price Band Details
The Anthem Biosciences IPO is a significant offering in 2025, with the company aiming to raise substantial capital through an Offer for Sale (OFS). Below is a detailed breakdown of the IPO specifics:
| Particulars | Details |
|---|---|
| IPO Opening Date | July 14, 2025 |
| IPO Closing Date | July 16, 2025 |
| Allotment Date | July 17, 2025 |
| Listing Date | July 21, 2025 |
| Issue Size | ₹3,395 Crore (100% OFS, 5.96 crore equity shares) |
| Price Band | ₹540 to ₹570 per share |
| Lot Size | 26 shares |
| Minimum Investment (Retail) | ₹14,820 (26 shares at ₹570) |
| Face Value | ₹2 per share |
| Market Cap | ₹31,867.39 Crore |
| Listing Exchanges | BSE and NSE |
| Book-Running Lead Managers | JM Financial, Citigroup Global Markets, J.P. Morgan India, Nomura |
| Registrar | KFin Technologies Limited |
The IPO is entirely an Offer for Sale (OFS), meaning the company will not receive any proceeds, and all funds will go to the selling shareholders after deducting offer-related expenses.
About Anthem Biosciences Limited
Founded in 2006 and headquartered in Bengaluru, Anthem Biosciences is a technology-driven CRDMO with a global footprint. The company provides end-to-end services across drug discovery, development, and manufacturing, catering to both emerging biotech startups and large pharmaceutical giants. Anthem specializes in fermentation-based Active Pharmaceutical Ingredients (APIs) such as probiotics, enzymes, peptides, vitamin analogues, and biosimilars.
Key Highlights of Anthem Biosciences
- Global Reach: Serves over 425 customers across 44+ countries, including the U.S., Europe, and Japan.
- Innovation-Driven: Holds 8 granted patents (1 in India, 7 overseas) and 24 pending global patent applications.
- Diverse Portfolio: Engages in 196 active projects, including 170 discovery projects and 284 unique molecules synthesized.
- Expert Team: Employs over 600 professionals, including medicinal chemists, microbiologists, and chemical engineers.
- Advanced Facilities: Operates three manufacturing units in Bengaluru, with a fourth (Unit III) expected to be completed by mid-2025.
Anthem Biosciences IPO Market Lot Size
The minimum lot size for the Anthem Biosciences IPO is 26 shares, requiring retail investors to invest ₹14,820 per application. Investors are required to apply in multiples of this lot size.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 26 | ₹14,820 |
| Retail Maximum | 13 | 338 | ₹1,92,660 |
| S-HNI Minimum | 14 | 364 | ₹2,07,480 |
| B-HNI Minimum | 68 | 1,768 | ₹10,07,760 |
Financial Performance of Anthem Biosciences
Anthem Biosciences has shown robust financial growth, making it an attractive investment opportunity. Below is a snapshot of its financial performance for the last three fiscal years:
| Financial Year | Revenue (₹ Crore) | Profit After Tax (₹ Crore) | YoY Revenue Growth |
|---|---|---|---|
| FY 2023 | 1,134 | 385.2 | – |
| FY 2024 | 1,483.07 | 367.31 | 30.8% |
| FY 2025 | 1,930.29 | 451.26 | 30.15% |
Key Financial Metrics (FY 2025)
- P/E Ratio: 70.9x (based on FY25 earnings)
- EV/EBITDA: 45x
- Promoter Holding Post-IPO: 74.69% (down from 76.88%)
- EBITDA Margin: ~37% (projected for FY25)
The company’s consistent revenue growth and strong profitability highlight its potential in the high-growth CRDMO industry, valued at $7.3 billion and expected to double by 2028.
Grey Market Premium (GMP) and Expected Listing Price
The Grey Market Premium (GMP) reflects investor sentiment and speculative listing gains. As of July 11, 2025, the GMP for Anthem Biosciences IPO is reported at approximately ₹79 per share, indicating a potential listing premium of ~13.86% over the upper price band of ₹570. This suggests an estimated listing price of around ₹649 per share.
GMP Trend (July 2025):
- July 9: ₹67
- July 10: ₹95
- July 11: ₹79
Note: GMP is volatile and speculative. Investors should not base decisions solely on GMP but consider the company’s fundamentals and market conditions.
Anthem Biosciences IPO Allotment and Listing
- Allotment Date: The basis of allotment is expected to be finalized on July 17, 2025.
- How to Check Allotment Status:
- Visit the KFin Technologies website.
- Select “Anthem Biosciences IPO” from the dropdown menu.
- Enter your PAN, application number, or DP/Client ID.
- Click “Search” to view your allotment status.
- Listing Date: Shares are expected to list on BSE and NSE on July 21, 2025.
- Share Allocation:
- Retail: 35% of the issue
- QIB (Qualified Institutional Buyers): 50%
- HNI (High Net-worth Individuals): 15%
- Employee Quota: ₹8.25 Crore
Investors can apply online using UPI or ASBA through platforms like Zerodha, Upstox, 5Paisa, HDFC Bank, or SBI Bank.
Strengths of Anthem Biosciences IPO
- Industry Leadership: One of India’s few CRDMOs with integrated capabilities in New Chemical Entities (NCE) and New Biological Entities (NBE).
- Global Clientele: Serves over 550 clients, including major pharmaceutical companies, with an average client relationship of 11 years.
- High-Growth Sector: Positioned to benefit from the global shift away from Chinese suppliers and the growing CRDMO market.
- Expansion Plans: Plans to increase fermentation and synthesis capacity by 50% over the next 12–18 months.
- Innovation Focus: Expertise in advanced modalities like biotransformation, flow chemistry, and green chemistry.
Risks to Consider
- 100% OFS: The company will not receive any proceeds, limiting funds for growth initiatives.
- High Valuation: A P/E ratio of 70.9x may indicate an expensive valuation compared to peers like Divi’s Laboratories and Syngene International.
- Geographic Risk: All manufacturing facilities are located in Bengaluru, increasing exposure to regional disruptions.
- Regulatory Compliance: The company’s operations are subject to stringent regulatory audits, and non-compliance could impact business.
Should You Invest in Anthem Biosciences IPO?
The Anthem Biosciences IPO offers exposure to a fast-growing, innovation-driven company in the CRDMO sector. Its strong financials, global client base, and expansion plans make it an attractive long-term investment. However, the high P/E ratio and lack of fresh issue proceeds warrant caution. Investors should evaluate their risk appetite, consult SEBI-registered financial advisors, and review the Red Herring Prospectus (RHP) before applying.
Expert Opinion
Harshal Dasani, Business Head at INVasset PMS, highlights Anthem’s robust growth potential, noting its projected 30% revenue growth in FY25 and strong EBITDA margins. He emphasizes the company’s strategic positioning in the global CRDMO market, making it a compelling choice for investors seeking exposure to India’s pharmaceutical sector.
FAQs About Anthem Biosciences IPO
1. When does the Anthem Biosciences IPO open and close?
The IPO opens on July 14, 2025, and closes on July 16, 2025.
2. What is the price band and lot size of the IPO?
The price band is ₹540–₹570 per share, with a lot size of 26 shares.
3. How can I apply for the Anthem Biosciences IPO?
You can apply online using UPI or ASBA through platforms like Zerodha, Upstox, or your bank’s net banking portal.
4. What is the expected listing price based on GMP?
As of July 11, 2025, the GMP is ₹79, suggesting a listing price of around ₹649 per share.
5. When and how can I check the allotment status?
The allotment status can be checked on July 17, 2025, via the KFin Technologies website using your PAN, application number, or DP/Client ID.
6. Is the Anthem Biosciences IPO a good investment?
The IPO is attractive due to the company’s strong financials and growth potential, but the high valuation and OFS structure require careful consideration. Consult a financial advisor before investing.
Conclusion
The Anthem Biosciences IPO presents a unique opportunity to invest in a leading CRDMO with a strong global presence and robust financial performance. With a projected listing gain of ~14% based on current GMP, the IPO is likely to attract significant investor interest. However, the high P/E ratio and geographic concentration of facilities are notable risks. Long-term investors with a high-risk appetite may find this IPO appealing, given the company’s growth trajectory and the expanding CRDMO market. Always conduct thorough research and consult with financial experts before making investment decisions.
Disclaimer: This article is for informational purposes only and should not be considered investment advice. IPO investments carry market risks. Please review the RHP and consult SEBI-registered advisors before investing.
Also Read: IRCTC Ltd Share Price Target 2025, 2026, 2027, 2030, Expert Analysis & Forecast
